Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death.

van Harten AM, Buijze M, van der Mast R, Rooimans MA, Martens-de Kemp SR, Bachas C, Brink A, Stigter-van Walsum M, Wolthuis RMF, Brakenhoff RH.

Oncogenesis. 2019 Jun 17;8(7):38. doi: 10.1038/s41389-019-0147-x.


Establishment and Genetic Landscape of Precancer Cell Model Systems from the Head and Neck Mucosal Lining.

de Boer DV, Brink A, Buijze M, Stigter-van Walsum M, Hunter KD, Ylstra B, Bloemena E, Leemans CR, Brakenhoff RH.

Mol Cancer Res. 2019 Jan;17(1):120-130. doi: 10.1158/1541-7786.MCR-18-0445. Epub 2018 Sep 17.


Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck.

de Boer DV, Martens-de Kemp SR, Buijze M, Stigter-van Walsum M, Bloemena E, Dietrich R, Leemans CR, van Beusechem VW, Braakhuis BJM, Brakenhoff RH.

Oncotarget. 2017 May 16;8(58):97928-97940. doi: 10.18632/oncotarget.17880. eCollection 2017 Nov 17.


A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

EJNMMI Res. 2015 Mar 20;5:14. doi: 10.1186/s13550-015-0088-0. eCollection 2015.


Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC.

Nagel R, Stigter-van Walsum M, Buijze M, van den Berg J, van der Meulen IH, Hodzic J, Piersma SR, Pham TV, Jiménez CR, van Beusechem VW, Brakenhoff RH.

Mol Cancer Ther. 2015 Jun;14(6):1434-44. doi: 10.1158/1535-7163.MCT-14-0846. Epub 2015 Mar 25.


Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.

Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, Zanda M, van Dongen GA.

Cancer Res. 2014 Oct 15;74(20):5700-10. doi: 10.1158/0008-5472.CAN-14-1141. Epub 2014 Aug 21.


Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

Nucl Med Biol. 2014 Oct;41(9):749-57. doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25.


Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.

Vugts DJ, Heuveling DA, Stigter-van Walsum M, Weigand S, Bergstrom M, van Dongen GA, Nayak TK.

MAbs. 2014 Mar-Apr;6(2):567-75. doi: 10.4161/mabs.27415. Epub 2013 Dec 9.


Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ.

J Biol Chem. 2013 Oct 11;288(41):29562-72. doi: 10.1074/jbc.M113.498436. Epub 2013 Aug 26.


Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.

Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GW, van Dongen GA.

Nat Protoc. 2013 May;8(5):1010-8. doi: 10.1038/nprot.2013.054. Epub 2013 Apr 25.


CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties.

Martens-de Kemp SR, Brink A, Stigter-van Walsum M, Damen JM, Rustenburg F, Wu T, van Wieringen WN, Schuurhuis GJ, Braakhuis BJ, Slijper M, Brakenhoff RH.

Stem Cell Res. 2013 May;10(3):477-88. doi: 10.1016/j.scr.2013.02.004. Epub 2013 Feb 18.


[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.

Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC, Hendrikse NH, Eriksson J, van Dongen GA, Windhorst AD.

Nucl Med Biol. 2013 May;40(4):488-97. doi: 10.1016/j.nucmedbio.2013.02.002. Epub 2013 Mar 20.


Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.

Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.

Clin Cancer Res. 2013 Apr 15;19(8):1994-2003. doi: 10.1158/1078-0432.CCR-12-2539. Epub 2013 Feb 26.


Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.

Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM.

Mol Imaging. 2012 Feb;11(1):33-46.


Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.

Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA.

Mol Cancer Ther. 2012 Apr;11(4):1017-25. doi: 10.1158/1535-7163.MCT-11-0891. Epub 2012 Feb 7.


Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets.

Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA.

EJNMMI Res. 2011 Dec 1;1(1):31. doi: 10.1186/2191-219X-1-31.


Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.

Vugts DJ, Vervoort A, Stigter-van Walsum M, Visser GW, Robillard MS, Versteegen RM, Vulders RC, Herscheid JK, van Dongen GA.

Bioconjug Chem. 2011 Oct 19;22(10):2072-81. doi: 10.1021/bc200298v. Epub 2011 Sep 9.


Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.

Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen En Henegouwen PM, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):753-63. doi: 10.1007/s00259-010-1700-1. Epub 2011 Jan 6.


The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.

Maussang D, Langemeijer E, Fitzsimons CP, Stigter-van Walsum M, Dijkman R, Borg MK, Slinger E, Schreiber A, Michel D, Tensen CP, van Dongen GA, Leurs R, Smit MJ.

Cancer Res. 2009 Apr 1;69(7):2861-9. doi: 10.1158/0008-5472.CAN-08-2487. Epub 2009 Mar 24.


(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44. doi: 10.1007/s00259-009-1096-y. Epub 2009 Mar 4.


Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.

Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA.

Mol Cancer Ther. 2008 Aug;7(8):2288-97. doi: 10.1158/1535-7163.MCT-07-2384.


[The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients].

van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink GJ, Dijkmans BA, Aarden LA.

Ned Tijdschr Geneeskd. 2008 Jul 26;152(30):1672-7. Dutch.


Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.

Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. doi: 10.1007/s00259-008-0774-5. Epub 2008 May 20.


The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G.

Blood. 2007 Oct 1;110(7):2659-66. Epub 2007 Jul 3.


Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.

Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45. Epub 2006 Jul 11.


Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.


Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.

van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA.

Ann Rheum Dis. 2007 Feb;66(2):253-6. Epub 2006 Jun 22.


Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA.

Cancer Biother Radiopharm. 2003 Aug;18(4):655-61.


89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA.

J Nucl Med. 2003 Aug;44(8):1271-81.


Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma.

de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, Snow GB, Brakenhoff RH.

Int J Cancer. 2003 Mar 1;103(6):768-74.


Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.

van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brakenhoff RH.

Int J Cancer. 1999 Sep 9;82(6):837-45.


Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.

van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA.

Int J Cancer. 1998 Jul 3;77(1):13-8.

Supplemental Content

Loading ...
Support Center